Interferons in the Treatment of Multiple Sclerosis

Filipi, Mary L.; Jack, Samantha

doi:10.7224/1537-2073.2018-063

Cited by 63 publications

(29 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The additional benefit of ibuprofen in MS treatment is to prevent flu-like symptoms, which can be caused by injectable DMDs, for example, by interferon beta or glatiramer acetate. 25 Another drug with high prescription prevalence in our study was cholecalciferol (vitamin D3). This vitamin is often prescribed as an add-on to the established MS immunomodulatory and symptomatic therapies.…”

Section: Discussionmentioning

confidence: 75%

Treatment patterns in pediatric patients with multiple sclerosis in Germany—a nationwide claim-based analysis

Frahm¹,

Peters²,

Bätzing³

et al. 2021

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Background: The manifestation of multiple sclerosis (MS) in childhood and adolescence occurs in 3%−5% of all MS cases. However, the immunomodulatory and symptomatic treatment options in this population group are still limited. Objective: We aimed to elucidate the prescription frequency of medications used in pediatric patients with multiple sclerosis (PwMS) compared with the general population, considering the entire spectrum of medications prescribed. Methods: Based on nationwide outpatient drug prescription data and statutory health insurance (SHI) physicians’ claims data from 2018, we conducted a population-based cross-sectional study in Germany. Children and adolescents aged ⩽17 years ( n = 11,381,939) diagnosed with MS ( n = 613), and a matched (age, sex, and health insurance sector) control group ( n = 6130) were included. The prescription prevalence was measured as the proportion of MS patients with ⩾1 prescription. Results: Of the 613 pediatric PwMS with a median age of 16 years, 403 (65.7%) were female. For 15 out of the 18 different active agents analyzed, PwMS had a significantly higher prescription prevalence than the control group (Fisher’s exact test: p ⩽ 0.037). The most frequently prescribed drugs in PwMS were ibuprofen (28.4%; anti-inflammatory drug), cholecalciferol (23.0%; vitamin D3), and interferon beta-1a (21.5%; disease-modifying drug, DMD). The proportions of DMD prescriptions and antibiotic prescriptions were higher among PwMS aged 15–17 years than among those ⩽14 years (DMD: 43.4% vs 34.2%, p = 0.05; antibiotic: 34.1% vs 24.8%, p = 0.031). In contrast, younger PwMS were more likely to receive a prescription for anti-inflammatory/anti-rheumatic drugs (36.6% vs 26.5%, p = 0.02). Conclusion: Our study analyzing real-world medication data showed that interferon beta, anti-inflammatory drugs, and vitamins play an essential role in the treatment of pediatric PwMS. Future research should evaluate longitudinal treatment patterns of pediatric PwMS, paying particular attention to the time of diagnosis, time of first DMD initiation, and therapy switches.

show abstract

Section: Discussionmentioning

confidence: 75%

Treatment patterns in pediatric patients with multiple sclerosis in Germany—a nationwide claim-based analysis

Frahm¹,

Peters²,

Bätzing³

et al. 2021

Ther Adv Neurol Disord

View full text Add to dashboard Cite

show abstract

“…Correct application of IMDs by patients is of great importance in terms of avoiding side effects. Minor changes in the way of the administration of the IMTs may improve compliance 10,11 . In this respect, it is very important to give injection trainings to patients by MS professionals.…”

Section: Discussionmentioning

confidence: 99%

Why are the First-Line Therapies Used as Injections Discontinued in the Treatment of Multiple Sclerosis?

Şen

Terzı

2022

International Archives of Medical Research

View full text Add to dashboard Cite

Objective: Immunomodulatory therapies (IMTs) are used in the treatment of multiple sclerosis (MS) considering their efficacy and safety. Although other effective treatments have been used in recent years, the use of IMTs still continues. In this study, we aimed to reveal the reasons for the discontinuation of IMTs used as injections. Method: IMTs data of 1464 patients were collected and analysed from the Imed database, where 20-year data of the patients were entered by us. Groups were divided as; Interferon beta-1a subcutaneous (IFN-β1a SC), Interferon beta-1a intramuscular (IFN-β1a IM), glatiramer acetate (GA) and Interferon beta-1b (IFN-β1b). Age, gender, duration of illness, types of disease onset, time to start the injection, duration of injection therapy, and reason for discontinuation of patients were analysed. Results: The most common reason for discontinuation of treatments was found to be disease progression (20.13%, 28.14%, 19.64%, 23.87%). Side effects, increased attack frequency, patient demand, disease activity detection in imaging methods, and pregnancy planning followed the disease progression respectively. Conclusion: IMTs as an injection form are used in the treatment of MS, considering their effectiveness and reliability. The most common reason for discontinuing treatment is disease progression.

show abstract

“…Regarding type I IFN, it has long been implicated in the pathophysiology of MS mainly because of its protective role, with IFN-β being the oldest approved treatment for relapsing-remitting MS (RRMS) ( 53 ). There are currently four IFN-β approved drugs for the treatment of relapsing forms of MS, three of which are administered subcutaneously (SC), IFNβ-1b, IFN-β-1a, and most recently peginterferon β-1a, one intramuscularly: IFN-β-1a ( 54 ). Treatment with IFN-β confers a decrease of approximately 30% in the annualized relapse rate (ARR) ( 55 ).…”

Section: Type I Ifn In the Cns: Association With Clinical Phenotypesmentioning

confidence: 99%

The role of type I IFN in autoimmune and autoinflammatory diseases with CNS involvement

et al. 2022

View full text Add to dashboard Cite

Type I interferons (IFNs) are major mediators of innate immunity, with well-known antiviral, antiproliferative, and immunomodulatory properties. A growing body of evidence suggests the involvement of type I IFNs in the pathogenesis of central nervous system (CNS) manifestations in the setting of chronic autoimmune and autoinflammatory disorders, while IFN-β has been for years, a well-established therapeutic modality for multiple sclerosis (MS). In the present review, we summarize the current evidence on the mechanisms of type I IFN production by CNS cellular populations as well as its local effects on the CNS. Additionally, the beneficial effects of IFN-β in the pathophysiology of MS are discussed, along with the contributory role of type I IFNs in the pathogenesis of neuropsychiatric lupus erythematosus and type I interferonopathies.

show abstract

Interferons in the Treatment of Multiple Sclerosis

Cited by 63 publications

References 70 publications

Treatment patterns in pediatric patients with multiple sclerosis in Germany—a nationwide claim-based analysis

Treatment patterns in pediatric patients with multiple sclerosis in Germany—a nationwide claim-based analysis

Why are the First-Line Therapies Used as Injections Discontinued in the Treatment of Multiple Sclerosis?

The role of type I IFN in autoimmune and autoinflammatory diseases with CNS involvement

Contact Info

Product

Resources

About